Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Nov 3, 2026.

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Philip J.M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse and 44 more

Cell · 2021 · CC BY

doi:10.1101/2020.11.07.365726

Abstract

Summary The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high dose challenge, resulting in strongly reduced viral infection and replication in upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.

References 82

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.
    Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity · 2015
    No notice
  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  11. 11.
    Self-assembling protein nanoparticles in the design of vaccines · 2015
    No notice
  12. 12.
    A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism · 2015
    No notice
  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  20. 20.
    Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells · 2017
    No notice
  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.
    Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus · 2019
    No notice
  27. 27.
    Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence · 2019
    No notice
  28. 28.
    Canu: scalable and accurate long-read assembly via adaptive k -mer weighting and repeat separation · 2017
    No notice
  29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  30. 30.
    Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle · 2019
    No notice
  31. 31.
    Longshot enables accurate variant calling in diploid genomes from single-molecule long read sequencing · 2019
    No notice
  32. 32.
    Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR · 2020
    Expression of concern
  33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  37. 37.
    Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping · 2020
    No notice
  38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  41. 41.
    Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients · 2020
    No notice
  42. 42.
    Cell entry mechanisms of SARS-CoV-2 · 2020
    No notice
  43. 43.
    Development of an inactivated vaccine candidate for SARS-CoV-2 · 2020
    No notice
  44. 44.
    Site-specific glycan analysis of the SARS-CoV-2 spike · 2020
    No notice
  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  46. 46.
    DNA vaccine protection against SARS-CoV-2 in rhesus macaques · 2020
    No notice
  47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  49. 49.
    Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020
    No notice
  50. 50.
    Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model · 2020
    No notice
  51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  52. 52.
    Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses · 2020
    No notice
  53. 53.
    Structure-based design of prefusion-stabilized SARS-CoV-2 spikes · 2020
    No notice
  54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  61. 61.
    Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate · 2020
    No notice
  62. 62.
    An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques · 2020
    No notice
  63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  67. 67.
    Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 · 2020
    No notice
  68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  69. 69.
    Stabilizing the closed SARS-CoV-2 spike trimer · 2021
    No notice
  70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  72. 72.
    SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice · 2021
    No notice
  73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  74. 74.
    S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates · 2021
    No notice
  75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.